Lead Product(s) : SOT112
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Synaffix
Deal Size : Undisclosed
Deal Type : Licensing Agreement
SOTIO Expands ADC Pipeline, Synaffix Pact for Two Bispecific Candidates
Details : under the license and option agreement with Synaffix. Sotio will obtain the Synaffix’s technology to develop two bispecific antibody-drug conjugate (ADC) programs.
Product Name : SOT112
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
March 13, 2025
Lead Product(s) : SOT112
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Synaffix
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : SOT109
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SOTIO Unveils Preclinical Data on SOT109 ADC for Colorectal Cancer
Details : SOT109 is a next-genaration antibody-drug conjugate targeting Cadherin-17 (CDH17), which is currently being evaluated for the treatment of Colorectal Cancer.
Product Name : SOT109
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
March 03, 2025
Lead Product(s) : SOT109
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SOT106
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : LegoChem Biosciences
Deal Size : Undisclosed
Deal Type : Agreement
Details : SOT106 is a novel ADC based on SOTIO Biotech’s proprietary antibodies and LCB’s industry-leading ConjuAll™ ADC platform technology with potential best-in class efficacy, safety and tolerability currently in preclinical development against multiple ...
Product Name : SOT106
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
November 29, 2022
Lead Product(s) : SOT106
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : LegoChem Biosciences
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : SOT102
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SOT102 demonstrated favorable tolerability and pharmacokinetic properties, with the latter substantiated by observed half-lives in the range of eight days and 13 days in cynomolgus monkey and rat, respectively.
Product Name : SOT102
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
December 04, 2021
Lead Product(s) : SOT102
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable